N/A
Manufactured by Carma Laboratories, Inc.
8 FDA adverse event reports analyzed
Last updated: 2026-04-15
OCTINOXATE, OXYBENZONE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Carma Laboratories, Inc.. The most commonly reported adverse reactions for OCTINOXATE, OXYBENZONE include APPLICATION SITE EXFOLIATION, APPLICATION SITE PAIN, APPLICATION SITE SWELLING, EYE IRRITATION, HYPOAESTHESIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for OCTINOXATE, OXYBENZONE.
Out of 2 classified reports for OCTINOXATE, OXYBENZONE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 8 FDA FAERS reports that mention OCTINOXATE, OXYBENZONE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include APPLICATION SITE EXFOLIATION, APPLICATION SITE PAIN, APPLICATION SITE SWELLING, EYE IRRITATION, HYPOAESTHESIA, OCULAR HYPERAEMIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Carma Laboratories, Inc. in connection with OCTINOXATE, OXYBENZONE. Always verify the specific product and NDC with your pharmacist.